Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 19 September 2013 | By Alexander Gaffney, RAC,
As Murphy's Law tells us, anything that can go wrong, will go wrong-a painfully obvious adage to anyone who has ever managed to expose their eyes to caustic or otherwise dangerous chemicals. Now the US Food and Drug Administration (FDA) is proposing a meeting to figure out how best to regulate the product needed to respond to such a calamity.
The products in question are known as emergency first aid eyewash drug products (EE products), and include a wide range of products used to treat ocular exposure to acids, alkalis, particulates or other hazards. The products are understood by FDA to be comprised of two component parts: the solution itself, and the delivery mechanism.
In an 18 September 2013 Federal Register notice, FDA explained that the solutions are currently on the market as both sterile and non-sterile formulations, and generally in two different forms. Ready-to-use products are pre-filled canisters or bags of solution which can be used rapidly, usually for small-volume purposes. Concentrated solutions and additives, meanwhile, are meant to be mixed with potable water for use in large-volume eyewash stations.
The products currently inhabit somewhat of a complicated place within FDA's regulatory framework, the agency explained.
FDA is currently considering the products for inclusion within an OTC drug monograph system, which would allow them to be manufactured and sold more easily so long as they adhered to the monograph and good manufacturing practices. The current monograph for OTC ophthalmic drug products was published in 1988, but notably calls for the products to be sterile.
However, the monograph never contained reference to EE products because safety and efficacy data had not been submitted to FDA at the time of its release. In 1989 FDA issued a call for such data, and in February 2003 proposed to amend the OTC monograph to include EE products through proposed rulemaking (PR) based on a positive assessment of the data it received.
However, the PR has never been finalized, and in the meantime FDA has been exercising what it calls "enforcement discretion"-in practical terms, meaning it won't go after manufacturers who act in good faith and in compliance with all other parts of the law-to permit EE products to be marketed as OTC products while the final monograph remains under development.
Now, however, FDA says it believes additional data and information are required in order to finalize the OTC monograph, and has proposed holding a hearing on the subject. At issue: How should EE products be controlled with respect to formulation, manufacturing and labeling?
The 4 December 2013 meeting will reportedly focus on six core questions:
Federal Register Notice
Tags: OTC
Regulatory Focus newsletters
All the biggest regulatory news and happenings.